Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market

Aug 14, 2014

Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma

Aug 11, 2014

Cellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common Stock

Jun 13, 2014

Cellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2014

Cellectar Biosciences Appoints Chad J. Kolean Chief Financial Officer

May 29, 2014

Cellectar Biosciences Reports First Quarter 2014 Financial Results and Recent Highlights

May 14, 2014

Cellectar Biosciences to Host Conference Call on May 14th to Discuss First Quarter 2014 Results and Provide Quarterly Update on Development Progress

May 12, 2014

Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration

May 5, 2014

Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences

Apr 2, 2014

Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights

Mar 25, 2014
    • 1...
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    © 2022 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A